Chemotherapy of stage IIIB and IV non-small-cell lung cancer.
Currently, lung cancer is a leading cause of death in men with more than half million new cases diagnosed every year. Eighty percent of these tumors are non-small-cell carcinoma and 70% of these are unresectable or metastatic at the time of presentation, resulting in dramatically poor survival rates. The increasing number of drugs showing a significant activity against non-small-cell lung cancer and the widespread use of modern cisplatin based regimens offer some hope of progress and suggest that chemotherapy may have a role in treating this disease. A recent meta-analysis has confirmed the modest but significant survival benefit for patients treated with combined chemotherapy both in case of metastatic disease and in addition to radiotherapy, in locally advanced disease.
Cojean
I
I
Service de Médecine B, Institut Gustave-Roussy, Villejuif, France.
Le Chevalier
T
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000970:Antineoplastic Agents